Clinical trials: Immunization; Infection
Coronary Artery Disease
Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study
Background: Influenza vaccination is recommended in patients (pts) with cardiovascular disease, however there is a shortage of clinical studies proving its protective effect on clinical course of coronary artery disease (CAD).
- Trial name
- NCT00371098
- Testing
- Influenza vaccination: Influvac (SolvayPharma)
- Where
- Poland
- Volunteers
- 658 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Healthy Participants
Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
Children are particularly vulnerable to respiratory virus infections, especially influenza. Vitamin A \& D deficiencies are associated with vulnerability to infectious diseases of the respiratory tract.
- Trial name
- NCT02649192
- Testing
- Influenza virus vaccine, Vitamins A and D
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
High and Low Resource Interventions to Promote HPV Vaccines
Human Papillomavirus (HPV) is a significant public health issue affecting nearly 14 million people in the United States. HPV can lead to cervical, oropharyngeal, anal, and penile cancers as well as genital warts.The purpose of…
- Conditions
- Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication
- Trial name
- NCT03824093
- Testing
- AFIX Only, AFIX+ Provider Communication Training
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease, Meningococcal Meningitis
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10
This was a Phase 2b/3, multi-center, extension study of V72P10 to assess antibody persistence at 18 months after the vaccination course in study V72P10 (NCT00661713).
- Trial name
- NCT01148524
- Testing
- No Vaccine, rMenB+OMV-NZ
- Where
- 6 sites in Chile
- Volunteers
- 817 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Hepatitis C
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
This study aims to identify the innate and adaptive immune response to zoster vaccination. Half of the participants will be individuals with chronic hepatitis C, while the other half with healthy volunteers.The innate immune…
- Trial name
- NCT02590068
- Testing
- Zoster vaccine live
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Communicable Diseases
Vaccine Social Media Randomized Intervention Trial
This study will assess the effectiveness of social media website devoted to vaccines to change immunization knowledge, perceptions and behavior.
- Trial name
- VSMRCT (NCT01873040)
- Testing
- Social Media plus information pages, Vaccine Information Pages
- Where
- United States
- Volunteers
- 1,675 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Spinal Cord Injuries, Traumatic Spinal Cord Injury
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2).
- Conditions
- Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine
- Trial name
- SCIVAX (NCT05869968)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers
Tat is a key HIV regulatory protein produced very early after infection, prior to virus integration, and necessary for viral gene expression, cell-to-cell virus transmission and disease progression.
- Trial name
- ISS T-003 (NCT01513135)
- Testing
- Tat
- Where
- South Africa
- Volunteers
- 200 people
- Sponsor
- Barbara Ensoli, MD
Malaria
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
Malaria, a disease caused by the parasite Plasmodium, is one of the world's major infectious diseases. With approximately 627.000 deaths a year, it is both a chief cause of morbidity and mortality as well as a significant…
- Trial name
- BMGF2b (NCT02098590)
- Testing
- CPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF166.C8
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Vaccination, Covid19
The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions
Uptake of vaccination against COVID-19 is key to controlling the pandemic. However, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have about its side effects…
- Trial name
- NCT04813770
- Testing
- Theory-based messages, General messages
- Where
- United Kingdom
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic…
- Trial name
- NCT05589844
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
SARS-CoV-2
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM…
- Trial name
- NCT05181709
- Testing
- Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sean Liu
COVID-19
COVID Booster in Pregnancy and Lactation
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
- Trial name
- NCT05543993
- Testing
- Bivalent COVID-19 Booster
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Covid 19, BCG Vaccination
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study
Covid-19 In Tunisia: AN Observational Cross-Sectional Registry Study
- Trial name
- CONNAITRE (NCT04384614)
- Testing
- Test PCR, TDR, Clinical Examination
- Where
- Tunisia
- Sponsor
- Direction des Soins de Santé de Base
Diabetes, Chronic Kidney Disease
Vaccination Coverage and Level of Protection in Patients at Risk
The purpose of this study is to determine 1. vaccination coverage of recommended vaccines (routine childhood vaccines and vaccines against seasonal flu and pneumococci) in children with chronic diseases (allergy, cystic fibrosis…
- Conditions
- Diabetes, Chronic Kidney Disease, Allergy, Cystic Fibrosis
- Trial name
- NCT03820752
- Where
- Belgium
- Volunteers
- 2,179 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Hiv, HIV I Infection
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals.
- Trial name
- NCT06805656
- Testing
- Maraviroc, Dolutegravir, Dendritic Cell Vaccine
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo